Related Experiment Videos
[Clinical analysis of multidrug-resistant tuberculosis]
T Yagi1, F Yamagishi, Y Sasaki
1Division of Thoracic Disease, National Chiba-Higashi Hospital, Chiba 260-8712, Japan.
Kekkaku : [Tuberculosis]
|January 25, 2002
Summary
Multidrug-resistant tuberculosis (MDR-TB) poses significant challenges due to drug resistance. Early detection and proper treatment are crucial to prevent the spread of this severe form of tuberculosis.
Area of Science:
- Pulmonology
- Infectious Diseases
- Microbiology
Context:
- Retrospective study of 43 multidrug-resistant tuberculosis (MDR-TB) patients at National Chiba-Higashi Hospital (1993-1997).
- MDR-TB defined as resistance to isoniazid and rifampicin.
- High prevalence of smear positivity (93.0%) and cavitary lesions (88.4%) on admission.
Purpose:
- To analyze the characteristics, treatment outcomes, and challenges associated with MDR-TB.
- To highlight the importance of early diagnosis and intervention in managing MDR-TB.
Summary:
- Out of 1627 pulmonary tuberculosis patients, 43 (2.6%) had MDR-TB.
- Most MDR-TB cases (37/43) were previously treated.
- Comorbidities included diabetes mellitus, cancer, and alcohol dependence.
- Surgical treatment showed success in three operated patients.
- Treatment outcomes: 16 cured, 8 ongoing, 13 died.
- Drug resistance complicates treatment and necessitates long-term hospitalization.
Impact:
- MDR-TB treatment is challenging due to cross-resistance to other drugs.
- Long-term hospitalization is required to prevent transmission.
- Emphasizes the critical need for early tuberculosis case finding and adherence to treatment.
- Directly Observed Therapy (DOT) is vital to prevent treatment dropout and emergence of MDR-TB.
- Urgent development of new anti-tuberculosis agents is essential.